The endothelium in atherogenesis

Lupus

Volumn 9, Issue 3, 2000, Pages 189-193

  Hunt, B J ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Atheroma; Endothelium

Indexed keywords

HLA ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN;

ANTIPHOSPHOLIPID SYNDROME; ATHEROGENESIS; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; INFLAMMATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0034118121     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828244     Document Type: Review

References (40)

1. Willms-Kretschmer K, Flax MH, Cotran RS. The fine structure of the vascular response in hapten-specific delayed hypersensitivity and contact dermatitis. Lab Invest 1967; 17: 334-349.
2. Pober J S. Cytokine-mediated activation of vascular endothelium. Am J Pathol 1988; 133: 426-433.
3. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343:831-836.
4. Bach FH, Robson SC, Winkler H et al. Barriers to xenotransplantation. Nature Med 1995; 1: 869-873.
5. Mantovani A, Sozzani A, Vecchi A et al. Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb Haemost 1997; 78: 406-414.
6. Pober JS, Orosz CG, Rose ML, Savage CO. Can graft endothelial cells initiate a host antigraft immune response? Transplantation 1996; 61: 343-349.
7. De Waard V, van de Berg BMM, Veken J et al. Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus. Gene 1999; 226: 1-8.
8. Baldwin AS. The NF-κB and 1κB proteins: new discoveries and insights. Ann Rev Immunol 1996; 14: 649-681.
9. Brand K, Page S, Rogler G et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-1722.
10. De Cataerina R, Libby P, Peng HB et al. Nitric oxide decreases cytokine-induced endothelial cell activation. Nitric oxide selectively reduces endothelial cell activation expression of adhesion molecules and proinflammaotry cytokines. J Clin Invent 1995; 96: 60-68.
11. Rajavashisth TB, Yamada H, Mishra NK. Transcriptional activation of the MOSF gene by minimally modified LDL: involvement of NFκB. Arterioscler, Thromb Vasc Biol 1995; 15: 1591-1598.
12. Meroni P, Khamashta MA, Younou P, Shoenfield Y. Mosaic of antiendothelial cell antibodies. Review of the first International Workshop on antiendothelial cell antibodies, clinical and pathological significance. Lupus 1995; 4: 95-99.
13. Bierhaus A, Klevesath M, Illmer T et al. Ligands of RAGE mediate continuous NE-κB activation, that results in persistent endothelial tissue factor induction. Thromb Haemost 1997; Suppl 1: 595.
14. Chappell L,C, Seed PT, Briley A et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 1999; 354: 810-816.
15. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
16. Ross R. Atherosclerosis-an inflammatory disease. N Enql J Med 1999; 340: 155-126.
17. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-20966.
18. Libby P, Mach F, Schonbeck U et al. Regulation of the thrombotic potential of athermoa. Thromb Haem 1999; 82: 736-741.
19. Westerman EM, Miles JM, Backonja M, Sundstrom WR. Neuropathological findings in multi-infarct dementia associated with anti-cardiolipin antibodies. Arthritis Rheum 1992; 35: 1038-1041.
20. Creamer D, Black MM, Calonje E. Reactive angioendotheliomatosis in association with the antiphospholipid syndrome.
21. Alarcon-Segovia D, Cardiel MH, Reyes E. Antiphospholipid arterial vasculopathy. J Rheumatol 1989; 16: 762-767
22. Drew P, Asherson RA, Zuk RJ et al. Aortic occlusion in systemic lupus erythematosis associated with antiphospholipid antibodies. Ann Rheum Dis 1987; 46: 612-661.
23. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant 1992; 11: S38-44.
24. Salamon RN, Hughes CCW, Schoen FL. Huamn coronary transplantation associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 1990; 138: 791-798.
25. Dunn MJ, Crisp SJ, rose ML et al. Anti-endothelial antibodies and coronary artery disease after transplantation. Lancet 1992; 339: 1566-1570.
26. Jurcervic S, Dunn MJ, Crisp S et al. A new ELISA to measure antiendothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclopsporine. Transplantation 1998; 65: 1197-1202.
27. Cervera R, Khamashta MA, Font J et al. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity 1991; 11: 1-6
28. Hill MB, Phipps JL, Malia et al. Characterisation and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in the primary antiphospholipid syndrome. Clin Exp Immunol 1995; 102: 368-372.
29. Simantov R, LaSala JM, Lo SK et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-2219.
30. Del Papa N, Guidali L, Sala A et al. Endothelial cells as targets for antiphospholipid antibodies. Arthritis Rheum 1997; 40: 551-561.
31. Pierangeli SS, Colden-Stanfield M, Liu X et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 1997-2002.
32. Blank M, Shoenfield Y, Cabilly S et al. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by peptides. Proc Natl Acad Sci 1999; 96: 5164-5168.
33. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 1444-1456.
34. 2-glycoprotein I tohuman atherosclerotic plaques. Circulation 1999; 99: 2227-2230.
35. George J, Aprek A, Gilburd B et al. Induction of early atherosclerosis in LDL receptor deficient mice immunised with β2 glycoprotein I. Circulation 1998; 15: 1108-1115.
36. Barger AC, Beeuwkes R, Lainey LL, Silverman KJ. Vasa vasorum and neovascularisation of human coronary arteries. N Engl J Med 1984; 310: 175-177.
37. Milei J, Parodi JC, Alonson GF et al. Carotid rupture and intraplaue haemorrhage: immunophenotyping and role of cells involved. Am Heart J 1998; 136: 1096-1105.
38. Inuoe M, Itoh H, Ueda M et al. Vascular endothelial growth factor expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98: 2108-2116.
39. Gould AL, Rossouw JE, Santanello NC et al. Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation 1998; 97: 946-952
40. Essig M Vrtovnik F, Nguyen G, Sraer JD, Friedlander C. Lovastatin modulates in vivo and in vitro thep lasminogen activator/plasmin system of rat proximal tubular cells: role of gen geranylation and Rho proteins. J Am Soc Nephrol 1998; 9: 1385-1388.